EMA

Sanofi teams with non-profit on a landmark new drug for sleeping sickness

The EMA has offered its endorsement for fexinidazole, which is billed as the first all-oral drug for sleeping sickness.

Bernard Pécoul

The Drugs for Neglected Diseases initiative handled the clinical trial work for the drug, with its partners at Sanofi handling the application part. A group of 7 European countries packed the $62.5 million development campaign for the drug, with some added support coming from the Bill & Melinda Gates Foundation and Médecins Sans Frontières.

The drug was put through its clinical paces using a non-profit model. Sanofi will now manage the production and distribution end of the project.

“Fexinidazole is an entirely new chemical entity that has been developed through an alternative non-profit R&D model. It is the first new chemical entity to be developed by DNDi,” said Bernard Pécoul, DNDi’s executive director. 


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 42,100+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Head of Business Development
Wren Therapeutics Boston, MA
Life Sciences Venture Professional
Northpond Ventures Washington, DC
Senior Drug Discovery Oncologist
Schrödinger New York, NY

Visit Endpoints Careers ->